Intravenous immunoglobulin in the Guillain-Barre syndrome

BMJ

Volumn 313, Issue 7069, 1996, Pages 1399-1400

  Hamdalla, H H M ^a   Hawkes, C H ^a   Spokes, E G ^a   Bamford, J M ^b   Goulding, P J ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN A;

ADULT; AGED; CASE REPORT; DRUG CONTRAINDICATION; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LETTER; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; SKIN MANIFESTATION;

AGED; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; POLYRADICULONEUROPATHY; SKIN DISEASES;

EID: 0029822077     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.313.7069.1399c     Document Type: Letter

References (4)

1. Hughes RAC. Intravenous IgG in Guillain-Barre syndrome. BMJ 1996; 313: 376–7. (17 August.)
2. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Safety 1993; 9: 259.
3. Barucha C, McMillan JC. Eczema after intravenous infusion of immunoglobulin. BMJ 1987; 295: 1141.
4. Dutch Guillain-Barre Study Group. Treatment of Guillain-Barre syndrome with high dose immune globulins compared with methylprednisolone: a pilot study. Ann Neurol 1994; 35: 749–752.